Preemptive Versus Empirical Antifungal Therapy for High‐Risk, Febrile, Neutropenic Solid Tumor Patients in an LMIC Setting
The combined EIA/HRCT-based preemptive strategy is feasible and associated with reduced antifungal use without compromising patient outcomes in pediatric patients with solid tumors and prolonged neutropenia.
Authors
- Leslie Lehmann (ORCID: https://orcid.org/0000-0001-5558-4830)
- Iman Zaky
- Lobna Shalaby
- Omneya Hassanain (ORCID: https://orcid.org/0000-0001-5912-6773)
- Mohamed Zamzam
- Mervat El Anany
- Amr Kashef
- Alaa El Haddad
- Omnia Al‐Qadi
- Maggie Naguib
Institutions
- Cairo University (EG)
- Dana-Farber Cancer Institute (US)
- Children Cancer Hospital (EG)
- Dana-Farber/Boston Children's Cancer and Blood Disorders Center (US)
Publication Details
- Journal
- Pediatric Blood & Cancer
- Published
- 2025-12-30
- DOI
- https://doi.org/10.1002/1545-5017.70095
- Primary Topic
- Neutropenia and Cancer Infections
- Type
- article
- Field-Weighted Citation Impact
- 0.00